STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC Business

 STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC Business

STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC Business

Shots:

  • STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand
  • The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020
  • The acquisition follows STADA’s acquisition of GSK’s five OTC skincare brands-Ceridal, Eurax, Oilatum, Polytar, Savlon and pediatric cough remedies, Tixylix in EU and selected markets in the Asia-Pacific and Latin America regions

Click here ­to­ read full press release/ article | Ref: STADA | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post